低分子肝素治疗进展性脑梗死的疗效观察  

Effect of low molecular weight heparin on patients with progressive cerebral infarction

作　　者：李卫军[1] 李复雄[1] 

机构地区：[1]深圳市龙岗中心医院,广东深圳518116

出　　处：《临床医药实践》2005年第7期496-498,共3页Proceeding of Clinical Medicine

摘　　要：目的观察低分子肝素治疗进展性脑梗死的临床效果。方法分析24例应用低分子肝素治疗的进展性脑梗死患者并与未应用低分子肝素治疗的25例做分析对照,比较两组治疗前后纤维蛋白原和神经功能缺损评分。结果两组临床治愈率分别为87.5%和65%,统计学比较有显著差异(P<0.05)。治疗组在治疗前后纤维蛋白原变化有显著差异(P<0.01)。结论低分子肝素治疗进展性脑梗死临床疗效确切、安全可靠。Objective:To investigate the clinical effect of low molecular weigh heparin on patients with progressive stroke.Methods:24 patients with progressive stroke were treated with low molecular weight heparin,and 25 patients in control group were treated without low molecular weight heparin.The concentration of plasma fibrinogen and the score of neurologic impairment in experiment group were compared with control group.Results:The cute rates were 87.5% in treatment group and 65% in control group,the difference was significant (P<0.05).In addition,the difference of plasma fibrinogen between two groups was significant(P<0.01).Conclusion:Low molecular weight heparin is safe and effective in treating progressive stroke.

关 键 词：低分子肝素 进展性脑梗死 纤维蛋白原 

分 类 号：R743[医药卫生—神经病学与精神病学]